FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386272373> ?p ?o ?g. }

• W4386272373 endingPage "794" @default.
• W4386272373 startingPage "783" @default.
• W4386272373 abstract "Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody designed to achieve hemostasis in all hemophilia types, with subcutaneous administration. A previous trial of concizumab (explorer4) established proof of concept in patients with hemophilia A or B with inhibitors.We conducted the explorer7 trial to assess the safety and efficacy of concizumab in patients with hemophilia A or B with inhibitors. Patients were randomly assigned in a 1:2 ratio to receive no prophylaxis for at least 24 weeks (group 1) or concizumab prophylaxis for at least 32 weeks (group 2) or were nonrandomly assigned to receive concizumab prophylaxis for at least 24 weeks (groups 3 and 4). After a treatment pause due to nonfatal thromboembolic events in three patients receiving concizumab, including one from the explorer7 trial, concizumab therapy was restarted with a loading dose of 1.0 mg per kilogram of body weight, followed by 0.2 mg per kilogram daily (potentially adjusted on the basis of concizumab plasma concentration as measured at week 4). The primary end-point analysis compared treated spontaneous and traumatic bleeding episodes in group 1 and group 2. Safety, patient-reported outcomes, and pharmacokinetics and pharmacodynamics were also assessed.Of 133 enrolled patients, 19 were randomly assigned to group 1 and 33 to group 2; the remaining 81 were assigned to groups 3 and 4. The estimated mean annualized bleeding rate in group 1 was 11.8 episodes (95% confidence interval [CI], 7.0 to 19.9), as compared with 1.7 episodes (95% CI, 1.0 to 2.9) in group 2 (rate ratio, 0.14 [95% CI, 0.07 to 0.29]; P<0.001). The overall median annualized bleeding rate for patients receiving concizumab (groups 2, 3, and 4) was 0 episodes. No thromboembolic events were reported after concizumab therapy was restarted. The plasma concentrations of concizumab remained stable over time.Among patients with hemophilia A or B with inhibitors, the annualized bleeding rate was lower with concizumab prophylaxis than with no prophylaxis. (Funded by Novo Nordisk; explorer7 ClinicalTrials.gov number, NCT04083781.)." @default.
• W4386272373 created "2023-08-31" @default.
• W4386272373 creator A5002208362 @default.
• W4386272373 creator A5006879238 @default.
• W4386272373 creator A5006881585 @default.
• W4386272373 creator A5008757028 @default.
• W4386272373 creator A5010852837 @default.
• W4386272373 creator A5018632343 @default.
• W4386272373 creator A5020338512 @default.
• W4386272373 creator A5032482470 @default.
• W4386272373 creator A5032715971 @default.
• W4386272373 creator A5034073736 @default.
• W4386272373 creator A5038277854 @default.
• W4386272373 creator A5038597185 @default.
• W4386272373 creator A5047434427 @default.
• W4386272373 creator A5048998886 @default.
• W4386272373 creator A5050723834 @default.
• W4386272373 creator A5053311886 @default.
• W4386272373 creator A5056760268 @default.
• W4386272373 creator A5064079929 @default.
• W4386272373 creator A5065668226 @default.
• W4386272373 creator A5078411281 @default.
• W4386272373 creator A5085327582 @default.
• W4386272373 creator A5087552786 @default.
• W4386272373 creator A5089145301 @default.
• W4386272373 creator A5089722288 @default.
• W4386272373 date "2023-08-31" @default.
• W4386272373 modified "2023-10-14" @default.
• W4386272373 title "Phase 3 Trial of Concizumab in Hemophilia with Inhibitors" @default.
• W4386272373 cites W2022517684 @default.
• W4386272373 cites W2032093921 @default.
• W4386272373 cites W2124329650 @default.
• W4386272373 cites W2151560055 @default.
• W4386272373 cites W2535041295 @default.
• W4386272373 cites W2760631163 @default.
• W4386272373 cites W2888314705 @default.
• W4386272373 cites W2892811509 @default.
• W4386272373 cites W2905475559 @default.
• W4386272373 cites W2953117569 @default.
• W4386272373 cites W2969898037 @default.
• W4386272373 cites W2988935613 @default.
• W4386272373 cites W3033648600 @default.
• W4386272373 cites W3047046471 @default.
• W4386272373 cites W3062976875 @default.
• W4386272373 cites W3095014309 @default.
• W4386272373 cites W4221055191 @default.
• W4386272373 cites W4221100730 @default.
• W4386272373 doi "https://doi.org/10.1056/nejmoa2216455" @default.
• W4386272373 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37646676" @default.
• W4386272373 hasPublicationYear "2023" @default.
• W4386272373 type Work @default.
• W4386272373 citedByCount "1" @default.
• W4386272373 countsByYear W43862723732023 @default.
• W4386272373 crossrefType "journal-article" @default.
• W4386272373 hasAuthorship W4386272373A5002208362 @default.
• W4386272373 hasAuthorship W4386272373A5006879238 @default.
• W4386272373 hasAuthorship W4386272373A5006881585 @default.
• W4386272373 hasAuthorship W4386272373A5008757028 @default.
• W4386272373 hasAuthorship W4386272373A5010852837 @default.
• W4386272373 hasAuthorship W4386272373A5018632343 @default.
• W4386272373 hasAuthorship W4386272373A5020338512 @default.
• W4386272373 hasAuthorship W4386272373A5032482470 @default.
• W4386272373 hasAuthorship W4386272373A5032715971 @default.
• W4386272373 hasAuthorship W4386272373A5034073736 @default.
• W4386272373 hasAuthorship W4386272373A5038277854 @default.
• W4386272373 hasAuthorship W4386272373A5038597185 @default.
• W4386272373 hasAuthorship W4386272373A5047434427 @default.
• W4386272373 hasAuthorship W4386272373A5048998886 @default.
• W4386272373 hasAuthorship W4386272373A5050723834 @default.
• W4386272373 hasAuthorship W4386272373A5053311886 @default.
• W4386272373 hasAuthorship W4386272373A5056760268 @default.
• W4386272373 hasAuthorship W4386272373A5064079929 @default.
• W4386272373 hasAuthorship W4386272373A5065668226 @default.
• W4386272373 hasAuthorship W4386272373A5078411281 @default.
• W4386272373 hasAuthorship W4386272373A5085327582 @default.
• W4386272373 hasAuthorship W4386272373A5087552786 @default.
• W4386272373 hasAuthorship W4386272373A5089145301 @default.
• W4386272373 hasAuthorship W4386272373A5089722288 @default.
• W4386272373 hasConcept C111113717 @default.
• W4386272373 hasConcept C112705442 @default.
• W4386272373 hasConcept C126322002 @default.
• W4386272373 hasConcept C141071460 @default.
• W4386272373 hasConcept C168563851 @default.
• W4386272373 hasConcept C197934379 @default.
• W4386272373 hasConcept C203092338 @default.
• W4386272373 hasConcept C2777785397 @default.
• W4386272373 hasConcept C2778589496 @default.
• W4386272373 hasConcept C42219234 @default.
• W4386272373 hasConcept C44249647 @default.
• W4386272373 hasConcept C535046627 @default.
• W4386272373 hasConcept C71924100 @default.
• W4386272373 hasConcept C82789193 @default.
• W4386272373 hasConceptScore W4386272373C111113717 @default.
• W4386272373 hasConceptScore W4386272373C112705442 @default.
• W4386272373 hasConceptScore W4386272373C126322002 @default.
• W4386272373 hasConceptScore W4386272373C141071460 @default.
• W4386272373 hasConceptScore W4386272373C168563851 @default.
• W4386272373 hasConceptScore W4386272373C197934379 @default.

• next